• Profile
Close

Novel dual HIV maintenance therapy with nevirapine plus lamivudine retain viral suppression through 144 weeks—A proof-of-concept study

PLoS Neglected Tropical Diseases Sep 27, 2020

Kahlert CR, et al. - In this proof-of-concept study, researchers aimed at determining the feasibility and efficacy of NVP plus Lamivudine (3TC) as novel simplified HIV maintenance dual therapy (DT) strategy. Twenty cases receiving combined antiretroviral treatment (cART) and with fully suppressed HIV plasma viral load > 24 months–whereof > 6 months on an NVP- containing regimen—were switched to oral NVP plus 3TC for 24 weeks. Decision was then left on patients concerning whether to continue DT or return to the previous cART. After a total of 144 observation weeks, no failure was recorded in any of the patients. Further there was no difference in the frequency of low- level HIV-RNA detection from the period before randomization. Findings thereby suggest this dual HIV maintenance strategy as feasible and effective. Although the findings are surprising, the results do not support the use of this dual regimen because of the nature of a proof-of-concept study.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay